Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE To Create Single "Evaluation Pathway" For Clinical Technology In UK

This article was originally published in The Gray Sheet

Executive Summary

The U.K.'s National Institute for Health and Clinical Excellence (NICE) is developing a new work program to improve the process for identifying, evaluating and adopting effective new medical devices and diagnostics

You may also be interested in...



NICE To Seek Candidates For New-Tech Evaluation Program In First Half Of '10

Device and diagnostics companies should start thinking about products they would like to offer for evaluation under a new program in the U.K

NICE To Seek Candidates For New-Tech Evaluation Program In First Half Of '10

Device and diagnostics companies should start thinking about products they would like to offer for evaluation under a new program in the U.K

Reimbursement In Brief

MedCAC pharmacogenomics meeting: The Medicare Evidence Development and Coverage Advisory Committee will meet Jan. 27, 2010, in Baltimore to review evidence on the impact of pharmacogenomic testing on health outcomes in cancer patients. Specifically, the panel will assess assays that might be used as a guide for certain drug treatments for breast cancer, colon cancer, chronic myelogenous leukemia or metastatic colorectal cancer. The upcoming meeting is the third in a series of MedCAC discussions held this year on evidence supporting genetic and genomic screening (1"The Gray Sheet" May 25, 2009)

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel